Literature DB >> 10441598

The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer.

A Hubert, T Peretz, O Manor, L Kaduri, N Wienberg, I Lerer, M Sagi, D Abeliovich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10441598      PMCID： PMC1377998          DOI： 10.1086/302525

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN： 0002-9297            Impact factor:   11.025


× No keyword cloud information.
  17 in total

1.  BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2005-06-29

2.  Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.

Authors:  Stephen M Edwards; Zsofia Kote-Jarai; Julia Meitz; Rifat Hamoudi; Questa Hope; Peter Osin; Rachel Jackson; Christine Southgate; Rashmi Singh; Alison Falconer; David P Dearnaley; Audrey Ardern-Jones; Annette Murkin; Anna Dowe; Jo Kelly; Sue Williams; Richard Oram; Margaret Stevens; Dawn M Teare; Bruce A J Ponder; Simon A Gayther; Doug F Easton; Rosalind A Eeles
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

3.  Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Authors:  David J Gallagher; Mia M Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Stadler; Samson W Fine; Victor Reuter; Michael Zelefsky; Michael J Morris; Howard I Scher; Robert J Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark E Robson; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

4.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

Review 5.  The role of BRCA1 and BRCA2 in prostate cancer.

Authors:  Elena Castro; Rosalind Eeles
Journal:  Asian J Androl       Date:  2012-04-23       Impact factor: 3.285

6.  Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.

Authors:  Richard Walker; Alyssa Louis; Alejandro Berlin; Sheri Horsburgh; Robert G Bristow; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

7.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

8.  Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin.

Authors:  Luna Kadouri; Mark Temper; Tal Grenader; Dvorah Abeliovich; Tamar Hamburger; Tamar Peretz; Michal Lotem
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

9.  A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.

Authors:  Hanna Rennert; Dani Bercovich; Ayala Hubert; Dvora Abeliovich; Uri Rozovsky; Anat Bar-Shira; Sonya Soloviov; Letizia Schreiber; Haim Matzkin; Gad Rennert; Luna Kadouri; Tamar Peretz; Yuval Yaron; Avi Orr-Urtreger
Journal:  Am J Hum Genet       Date:  2002-07-23       Impact factor: 11.025

Review 10.  The role of the BRCA2 gene in susceptibility to prostate cancer revisited.

Authors:  Elaine A Ostrander; Miriam S Udler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.